KEYNOTE905: #Pembrolizumab + #EnfortumabVedotin before & after cystectomy improved EFS, OS & pCR vs surgery alone. A new SOC may be on the horizon for this high-risk group can’t wait to see the full data! #BladderCancer #Oncology #Immunotherapy #ADCake brando Andrea Necchi

Magnetic Resonance Imaging–led Risk-adapted Active Surveillance for #ProstateCancer sciencedirect.com/science/articl… This large cohort study of 1150 men on MRI-led active surveillance (AS) for prostate cancer shows that MRI visibility and baseline Gleason pattern 4 strongly predict

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 15-21, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅Brain🧠 Imaging in #BreastCancer ✅Update on IMvigor011 in #BladderCancer 🎗️ ✅AMPLIFY201 💉in #PancreaticCancer &

Ping: Matteo Lambertini, MD PhD Icro Meattini #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD Mario Balsa

🎉New publication! Metabolic-Immune Score (MIS) for advanced NSCLC on ICI — multidisciplinary work 🙏 Nuclear Medicine. 👉MIS = PET-CT metrics + LIPI➡️prognosis stratification. rdcu.be/eBKiy Scientific Reports Ankara Üniversitesi Emre Yekedüz Dr Joseph McCollom DO

🩸🧬Liquid biopsy is no longer future! Minimally invasive, biomarker-driven care! European Urology International Society of Liquid Biopsy Benjamin L Maughan Emmanuel Antonarakis Lars Dyrskjøt Petros Grivas Mehmet Asim Bilen,MD Matt Cooperberg Shilpa Gupta OncoAlert European Association of Urology (EAU) Alberto Briganti doi.org/10.1016/j.euru…

Cisplatin saves lives, but kidneys pay a price. 🔘1 in 7 pts develop Chronic Kidney Disease After Cisplatin Treatment. Baseline eGFR is the strongest predictor, check it, discuss risks, hydrate, avoid nephrotoxins. #Nephrology #Oncology JAMA Oncology OncoAlert Oncology Brothers Uromigos

🚨 New in Eur J Cancer: The #NABUCCO trial reports 5-year outcomes of pre-op ipilimumab+nivolumab in stage III #urothelialcancer: ✅ PFS 67% ✅ OS 70% Survival unaffected by residual NMIBC, micromets, or grade ≥3 irAEs. Promising durability for neoadjuvant ICB! OncoAlert

⭕️In a cohort of 86,632 adults with obesity, GLP-1 receptor agonists were linked to lower overall cancer risk. ⭕️Notably ↘️ risk: endometrial, ovarian, meningioma. ⭕️But signal for ↗️kidney cancer risk. Balance of benefit & caution. JAMA Oncology OncoAlert jamanetwork.com/journals/jamao…

Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk #ProstateCancer euoncology.europeanurology.com/article/S2588-… The PROFIT phase 3 trial evaluated long-term patient-reported outcomes (PROs) in

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 22-28, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅News from Industry: monarchE Update 🦋 ✅Immunotherapy Boosts Pathological Response in HR+/HER2– Early #BreastCancer

TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4) buff.ly/pZDcMxu The phase 2 SunRISe-4🌄 trial evaluated

🚨 The OncoAlert WEEKLY RoundUp (Aug 22–28, 2025) 🚨 GU Highlights: ✅ Short-Term ADT + High-Dose #Radiotherapy improves outcomes in localized #ProstateCancer

Important data. We are testing de-escalation in deep responders in the DE-ESCALATE trial. Anyone interested to join please contact tombal or me. We will discuss the topic Advanced Prostate Cancer Consensus Conference, register and participate in the discussions apccc.org

🧬 Stereo-seq V2 brings spatial transcriptomics to the clinic: it works directly on the FFPE tissue blocks you already use. 👉 Reveals tumor biology (e.g., TNBC) 👉 Tracks infections (e.g., TB, host–pathogen interactions) 👉 Maps immune repertoires for therapy guidance ➡️ A tool

🌍 𝗚𝗹𝗼𝗯𝗮𝗹 𝗩𝗼𝗶𝗰𝗲𝘀 𝗶𝗻 𝗥𝗲𝗻𝗮𝗹 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 (𝗩𝗜𝗥𝗢) 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 📅 Sept 11–12, 2025 | Chaired by Dr. Rana McKay (Rana McKay, MD, FASCO) & co-chaired by Dr. Yüksel Ürün (Yüksel Ürün) 🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲: forms.gle/qcQyaGMQfHDhan…

Call for abstracts is open. APCCC 2026 (Lugano, 30 Apr–2 May) is a space where evidence meets consensus in advanced prostate cancer. #APCCC26 Advanced Prostate Cancer Consensus Conference OncoAlert Prostate Cancer Foundation Uromigos #prostatecancer

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Aug28-Sept4, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅Neoadjuvant Pembrolizumab + Accelerated MVAC in Rare #BladderCancer Subtypes: Phase 2 Trial Results ✅Cytokine

A GREAT START TO #IUCS25 🇬🇧in Portsmouth as REPORTED by MedTrack Social MEDTRACK medtracksocial.com/hashtag/IUCS25/ USE MEDTRACK, its Free & Available for all Made by Colleagues, for Colleagues⚕️ Here is a more detail breakdown on Influence and Activity Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO

New systematic review (63 studies): 🌱 Plant-based, 🫒 Mediterranean & 🔥 anti-inflammatory diets = ↓ prostate cancer 📉 progression & mortality Hyperinsulinemic diets = ↑ risk ⚠️ 💪 Healthy eating = benefits for both 🩺 cancer & ❤️ heart health OncoAlert European Urology